Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented by John Mascarenhas, MD.
Trifluridine/tipiracil improved DFS in stage IV CRC with molecular residual disease but not in the full ALTAIR study population.
Burnout, emotional exhaustion, and depersonalization were more common in a 2023 survey than in a 2013 survey.
Dr. David S. Hong presents the preliminary Phase 1 results on RMC-9805, a first-in-class, oral, RAS(ON) G12D-selective inhibitor, highlighting its promising safety, pharmacokinetics, and early…
An umbrella review of components of reliance among patients with cancer compared 20 instruments to find 3 that are ideal for these patients.
R. Wendel Naumann, MD, discusses next-generation antibody-drug conjugates in ovarian cancer.
Stéphanie Lheureux, MD, PhD, discusses the evolution of antibody-drug conjugates since mirvetuximab soravtansine in ovarian cancer.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and…
In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States…
PURPOSEFinancial toxicity (FT) has been linked to higher symptom burden and poorer clinical outcomes for patients with cancer. Despite the availability of validated tools to…
